Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + tipifarnib
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Gemcitabine + tipifarnib is a combination of two small molecule chemotherapeutic agents used in clinical trials for the treatment of advanced solid tumors and pancreatic cancer. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA during replication and inhibiting ribonucleotide reductase, leading to masked chain termination and apoptosis of malignant cells. Tipifarnib (R115777) is an orally available farnesyltransferase inhibitor that blocks the post-translational modification (farnesylation) of proteins such as Ras, thereby interfering with signal transduction pathways involved in tumor growth. The combination has been evaluated for synergistic antitumor activity but did not show significant improvement in overall survival compared to single-agent gemcitabine in phase III trials for pancreatic cancer[2][3][5].
- Other names
- gemcitabine hydrochlorideR115777R-115777R 115777tipifarnib
02
Targets
DNA polymerase familyFTase (Protein Farnesyltransferase)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + tipifarnib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + tipifarnib.